Sinnott-Armstrong N, Naqvi S, Rivas M, Pritchard JK. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. Elife. 2021. https://doi.org/10.7554/elife.58615.
Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020;26:252–8.
Flynn E, Tanigawa Y, Rodriguez F, Altman RB, Sinnott-Armstrong N, Rivas MA. Sex-specific genetic effects across biomarkers. Eur J Hum Genet. 2021;29:154–63.
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:1–10.
R Core Team (2020). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2020.
Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: With illustrative examples from male and female populations. Steroids 2009;74:512–9.
Holmes D. Determine the CV of a calculated lab reportable—bioavailable testosterone. https://labrtorian.com/2017/08/07/determine-the-cv-of-a-calculated-lab-reportable-bioavailable-testosterone/.
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–72.
Choi SW, Mak TSH, O’Reilly PF Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020. https://doi.org/10.1038/s41596-020-0353-1.
Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006;85:1319–40.
Zeng X, Xie Yjie, Liu Yting, Long Slian, Mo Zcheng. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214–21.
Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581–606.
Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res. 2003;15:14–20.
Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care. 1994. https://doi.org/10.2337/diacare.17.5.405.
Haider A, Yassin A, Haider KS, Doros G, Saad F, Rosano GMC. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;12:251–61.
Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharmacol Ther. 2017;22:414–33.
Haider KS, Haider A, Saad F, Doros G, Hanefeld M, Dhindsa S, et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes, Obes Metab. 2020;22:2055–68.
Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9:32–45.
Vosberg DE, Syme C, Parker N, Richer L, Pausova Z, Paus T. Sex continuum in the brain and body during adolescence and psychological traits. Nat Hum Behav. 2021;5:265–72.